MSTN and muscular dystrophy: FST is of particular interest since follistatin is a natural myostatin antagonist and has been proposed as a target for treatment of muscular dystrophy by promotion of muscle growth and decreasing fibrosis.[22, 23] Upregulation of FST in COL6-RD subjects may reflect an active response to progressing fibrosis.